Regulatory bodies in Europe have already restricted valproate prescribing for women of childbearing age given its well-documented teratogenic profile — but whether a father's use of the drug during sperm formation poses similar risks to offspring has remained a genuinely open and consequential question for thousands of epilepsy patients planning families. This large Nordic study offers the most rigorous population-level answer yet.
Drawing on nationwide birth and prescription registries in Sweden and Norway, researchers tracked more than 2,000 children born to fathers who filled valproate monotherapy prescriptions in the three months preceding conception — the window corresponding to active spermatogenesis — and compared their neurodevelopmental outcomes against children whose fathers used lamotrigine or levetiracetam, two antiseizure medications with no known teratogenic signal. Follow-up extended from age one through 2022. After adjusting for relevant confounders and pooling both national cohorts via random-effects meta-analysis, paternal valproate exposure was not associated with elevated risk of any neurodevelopmental disorder overall (adjusted hazard ratio 1.06; 95% CI 0.81–1.22). Specific conditions including autism spectrum disorder (aHR 1.29; 95% CI 0.89–1.85) and ADHD (aHR 0.98; 95% CI 0.76–upper bound not shown in excerpt) showed similarly null or statistically non-significant associations.
This finding matters both clinically and biologically. Valproate inhibits histone deacetylases and is known to alter epigenetic marks — a plausible mechanism for transgenerational harm via sperm epigenome modification. Prior animal studies have raised this concern, making a null human result both reassuring and scientifically informative. However, several limitations warrant caution: exposure was defined by a single filled prescription, which may not reflect actual adherence or dose; sample sizes for specific NDD subtypes are modest, limiting power to detect small effects; and observational designs cannot fully eliminate residual confounding from paternal epilepsy severity itself. Overall, this is a well-designed, confirmatory-leaning study that should inform shared decision-making for male patients on valproate — though it does not wholly close the biological question of epigenetic transmission.